RFK Jr. remains HHS Secretary amid ongoing implementation of Make America Healthy Again priorities, including recent congressional testimony on budget cuts and agency restructuring, alongside the May 2026 dismissal of U.S. Preventive Services Task Force leaders. This record of active policy shifts on vaccines, preventive care guidelines, and chronic disease initiatives has sustained friction with congressional oversight and some external critics, contributing to trader uncertainty about tenure stability through year-end. The near-even odds reflect competing pressures: alignment with administration goals and lack of formal removal proceedings versus repeated hearings, staff transitions, and calls for accountability that keep departure risks in play. Scheduled budget and confirmation-related developments could shift sentiment if they escalate or resolve without incident.
基於Polymarket數據的AI實驗性摘要。這不是交易建議,也不影響該市場的結算方式。 · 更新於$23,307 交易量
$23,307 交易量
$23,307 交易量
$23,307 交易量
An announcement of Robert F. Kennedy Jr. (RFK Jr.)'s resignation/removal before this market's end date will immediately resolve this market to "Yes", regardless of when the announced resignation/removal goes into effect.
The resolution source for this market will be official information from Robert F. Kennedy Jr. (RFK Jr.) and the U.S. government; however, a consensus of credible reporting may also be used.
市場開放時間: Mar 19, 2026, 2:02 PM ET
Resolver
0x65070BE91...An announcement of Robert F. Kennedy Jr. (RFK Jr.)'s resignation/removal before this market's end date will immediately resolve this market to "Yes", regardless of when the announced resignation/removal goes into effect.
The resolution source for this market will be official information from Robert F. Kennedy Jr. (RFK Jr.) and the U.S. government; however, a consensus of credible reporting may also be used.
Resolver
0x65070BE91...RFK Jr. remains HHS Secretary amid ongoing implementation of Make America Healthy Again priorities, including recent congressional testimony on budget cuts and agency restructuring, alongside the May 2026 dismissal of U.S. Preventive Services Task Force leaders. This record of active policy shifts on vaccines, preventive care guidelines, and chronic disease initiatives has sustained friction with congressional oversight and some external critics, contributing to trader uncertainty about tenure stability through year-end. The near-even odds reflect competing pressures: alignment with administration goals and lack of formal removal proceedings versus repeated hearings, staff transitions, and calls for accountability that keep departure risks in play. Scheduled budget and confirmation-related developments could shift sentiment if they escalate or resolve without incident.
基於Polymarket數據的AI實驗性摘要。這不是交易建議,也不影響該市場的結算方式。 · 更新於
警惕外部連結哦。
警惕外部連結哦。
Frequently Asked Questions